Gene fusions involving ALK, ROS1, RET, and NTRK are now established targets in NSCLC, for which highly effective and well-tolerated kinase inhibitors are the preferred initial therapy. A growing body […] Read more
Surgical resection remains the gold standard for patients diagnosed with early-stage lung cancer, and since the early 1990s, video-assisted thoracoscopic surgery (VATS) lobectomy has been acknowledged as an effective – […] Read more